Isozymes of AMP-Deaminase in Muscles Myasthenia Gravis Patients by unknown
Isozymes of AMP-Deaminase in Muscles Myasthenia Gravis
Patients
Iwona M. Rybakowska1 • Stanisław Bakuła2 • Krystian Kaletha1
Accepted: 7 May 2016 / Published online: 13 May 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract Similar symptoms observed in Myasthenia
gravis (MG) can be also detected in the case of skeletal
muscle AMP-deaminase deficiency. We compared the
activity and expression of AMP-deaminase (AMPD)
products in skeletal muscles of MG patients and MG-free
individuals. The activity of AMP-deaminase in the muscles
of MG patients was significantly higher than in the controls
and was 2.05 lmol/min/mg protein (±0.31). The two
groups differ in level of AMPD product expression. Fur-
thermore in MG-group molecular size of isoform AMPD1
is 90 kDa in contrast to MG-free group where is present
70 kDa isoform of enzyme. The data suggests that the
disturbances in transmission of neuronal signaling, taking
place in the skeletal muscles of MG patients, may also
change energetic metabolism of the affected muscles by
changing molecular mass of isoform.
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Introduction
Myasthenia gravis (MG) is an acquired autoimmune dis-
ease of human neuromuscular system. MG manifests
clinically as abnormally easy fatigability of several groups
of skeletal muscles. Usually the symptoms begin in the
group of extraocular muscles which results in ptosis and
diplopia. Sometimes MG may be limited to these muscles
but usually progresses and involves other muscular groups,
including the respiratory system. The weakness and fati-
gability of the muscles usually grow worse in time (Porth
and Matfin 2009).
MG is a consequence of antibody-mediated decrease in
the number of acetylcholine receptors and resultant
impairment of neuromuscular transmission. Interestingly,
the majority (approximately 75 %) of MG patients present
with various degree of abnormalities in the morphological
structure of the persisted thymus (tumorous). This sub-
stantiates surgical removal of the thymus is one of the
widely used treatment methods of MG (Porth and Matfin
2009).
AMP-deaminase (AMPD-EC3.5.4.6) is an enzyme
involved in purine metabolism. It catalyses irreversible
deamination of AMP to IMP, and plays an important role in
the energetic metabolism of tissues, influencing the value
of the adenylate energy charge in the cell (Chapman and
Atkinson 1973). Moreover, AMPD participates in purine
nucleotide cycle of skeletal muscles (Lowenstein and
Goodman 1978). Various tissue- and stage-specific iso-
forms of AMPD have been identified in humans (Kaletha
and Nowak 1988; Ogasawara et al. 1982). Three main
AMPD isozymes, designated as M (muscle), L (liver) and
E (erythrocyte) forms, are encoded by AMPD1, AMPD2
and AMPD3 genes, respectively (Morisaki et al. 1990). At
least in rodents, neuromuscular junctions possess ecto-
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AMP deaminase activity which can dissociate extracellular
ATP catabolism from adenosine formation. Ecto-AMP
deaminase blunts the ATP derived adenosine A2A receptor
facilitation of acetylcholine release from stimulated motor
nerve endings, which may contribute to tetanic failure in
myasthenic individuals (Magalhaes-Cardoso et al. 2003,
Noronha-Matos et al. 2011).
Myoadenylate deaminase deficiency (mAMPDD) is a
frequent, relatively benign disorder of skeletal muscles.
Defect of AMPD in homo- and heterozygotic form occurs
in 20 % of population. We distinguish primal and deriva-
tive form of enzymopathy. Derivative form of muscle AMP
deaminase deficiency is result of skeletal muscle damage in
disease muscle and nervous systems. At this people instead
of reduction of AMPD activity is observed always decrease
activity of creatine kinase and adenylate kinase. Whereas
the primal form of defect is inherited autosomal and
recessive and follows from changing in chromosome 1
(1p13–p21). It manifests as muscle fatigue following
strenuous exercise (Fishbein et al. 1978, Fishbein 1985).
The deficiency is an autosomal recessive disorder resulting
from mutations of AMPD1. Its primary consequences
include impairment of muscle purine metabolism and
purine nucleotide cycle. Interruption of the cycle during
muscle exercise decreases the adenylate energy charge of
the myocyte and disturbs the rate of glycolysis and turn-
over of citric acid cycle (Flanagan et al. 1986; Sabina and
Mahnke-Zizelman 2000; Sinkeler et al. 1987).
Results showing high level of AMPD2 gene in hyper-
plastic, tumorous thymus in relation to AMPD1 and
AMPD3 (Rybakowska et al. 2015) may substantiates
AMPD participation in neurodegenerative disorder (Akizu
et al. 2013). Therefore, the aim of this study was to analyse
the expression level and selected physicochemical and
immunological properties of AMPD isolated from skeletal
muscles of patients with MG and MG-free individuals
operated in one surgery clinic.
Materials and Methods
We conduct our study on group of 25 MG-free individuals
and 25 MG patients.
The data we introduce included representative samples
of skeletal muscles (intercostal muscles) obtained intraop-
eratively from MG patients (18–38 years of age, subjected
to thymectomy) and MG-free individuals (60–68 years of
age, subjected to lobectomy due to lung cancer). The
material was immediately washed in saline solution and
frozen in liquid nitrogen.
The activity of AMPD was determined colorimetrically
(Chaney and Marbach 1962) in tissue homogenates. The
incubation medium, in the final volume of 0.5 ml,
contained 0.1 M potassium-succinate buffer, pH 6.5, with
1 mM concentration of the substrate AMP. After equili-
bration of temperature at 30 C, 25 ll of enzyme solution
(containg about 5 lg of enzyme protein) was added into
the incubation medium to start the reaction. The incuba-
tions were carried out for 15 min, and initial velocity of
reaction was determined from the mean amount of
ammonia liberated in three parallel incubations.
Protein concentration was determined according to
Bradford (Bradford 1976).
Total RNA was isolated according to Chomczynski and
Sacchi (1987), using 1:1 phenol–chloroform as an
extracting mixture. The extracted RNA was separated on
1 % agarose gel containing 30 % formaldehyde. Expres-
sion of the AMPD genes was determined by means of RT-
PCR, as described elsewhere (Roszkowska et al. 2008).
To isolate the enzyme, the tissue samples were
homogenized in 3 volumes (v/w) of extraction buffer
(0.089 M phosphate buffer, pH 6.5, containing 0.18 M KCl
and 1 mM mercaptoethanol with addition of 1 mM
phenylmethylsulfonyl fluoride (PMSF) and trypsin inhi-
bitor), and centrifuged (20 min at 3000 g). Subsequently,
SDS-PAG electrophoresis and Western blot analysis (with
the use of polyclonal antibodies kindly provided by Pro-
fessor R. Sabina) were performed as described elsewhere
(Szydłowska et al. 2004).
The measurements of enzyme activity and mRNA levels
were described as mean ± standard deviation (SD). Fig-
ures were done in Sigma Plot program. Differences between
groups were analyzed by 2-sided Student unpaired t test.
The protocol of the study was approved by the Local
Ethics Committee at the Medical University of Gdansk
(decision no. NKBBN/229/2012).
Results
The expressions of AMPD family genes in skeletal muscles
of MG patients and MG-free individuals are presented on
Fig. 1a–c. As shown on Fig. 1a, the expression of AMPD1
gene, physiologically most intensive in mature skeletal
muscles, was even more enhanced in the material from MG
patients. We did not observe similar phenomenon in the
case of AMPD3 gene. The expression of this gene in
muscles of MG patients showed trend of lower expression
in comparison with MG-free controls (Fig. 1c). The
expression of AMPD2 gene, extremely weak in mature
skeletal muscles of healthy individuals, was also weak in
the muscles of MG patients (Fig. 1b). Comparing all data
showing on Fig. 1 we can say that as well as in muscles
MG-free controls and MG patients the expressions of
AMPD1 is highest in contrast to thymus (Rybakowska
et al. 2015).
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The activity of AMPD in skeletal muscle extracts of the
two studied groups of patients is presented in Table 1. As
shown in the Table, the activity of AMPD in the extracts
obtained from MG patients (mean specific activity of about
2.05 lmol/min per mg of protein) was roughly 20 %
higher than in the extracts from MG-free controls (mean
specific activity about 1.64 lmol/min per mg of protein).
Figure 2 illustrates the results of Western blot analysis
performed with the prevailing enzyme isoform present in
skeletal muscle extracts of the two analyzed groups of
patients on representative samples (we observed the same
in all studied samples). As shown on the figure, the two
groups differ in immunological reaction with anti-AMPD1
antibodies. While a protein weighing about 90 kDa was
labeled in the extracts from MG patients, another protein
with ca. 20 kDa lower molecular mass was detected in the
extracts from MG-free individuals.
Discussion
The intracellular pool of ATP changes in response to
metabolic conditions, and strenuous muscle exercise was
shown to be associated with a decrease in the ATP/ADP
ratio (Flanagan et al. 1986; Sinkeler et al. 1987). A
reduction of cellular pH, taking place in exercising skeletal
muscles, stimulates the activity of purine nucleotide cycle
in order to counteract the decrease in the cellular ATP/ADP
ratio (AMPD is inhibited during the initial phase of exer-
cise due to accumulation of orthophosphate, but is reacti-
vated by lowered pH) (Hellsten et al. 1999; Makarewicz
and Stankiewicz 1974). Stimulation of purine nucleotide
cycle activity augments energy production in exercising
skeletal muscles [to a degree dependent on the metabolic
type of the muscle (Meyer and Terjung 1979)]; the energy
comes from both glycolysis and anaplerotic reaction of the
citric acid cycle (Sinkeler et al. 1987; S´cisłowski et al.
1982). In view of its role in normalization of ATP to ADP
ratio, prompt activation of AMPD seems vital for the
maintenance of skeletal muscle contractility during periods
Fig. 1 Expressions of AMPD family genes in representative skeletal
muscles of MG patients (MG) and MG-free controls (C). mRNA of
AMPD1 isoform (a); mRNA of AMPD2 isoform (b); mRNA of
AMPD3 isoform (c). The expressions were defined as a ratio of
constitutively expressed ACTIN. Expression levels were compared
with the Student’s t test, n = 4 in group, (p\ 0.05)
Table 1 Specific activities of
AMPD in skeletal muscle
extracts from MG and MG-free
patients
Tissue Specific activity (lmol/min/mg of protein)
Skeletal muscle of MG patients 2.05* (±0.31)
Skeletal muscle of MG-free controls 1.64 (±0.23)
The enzymatic activity presented as the mean value ± SD. Statistical significance verified with the Stu-
dent’s t test, n = 4 in group, * p\ 0.05
Fig. 2 Western blot analysis of AMPD1 in skeletal muscle extracts
obtained from MG patients (MG) and MG-free controls (C).
Monoclonal antibodies against AMPD1 isozyme were used for
immunological staining of the blot. Protein standards (ST)
Int J Pept Res Ther (2016) 22:511–515 513
123
of higher energy demand (Flanagan et al. 1986; Sinkeler
et al. 1987).
Previous experimental studies showed that binding of
this enzyme to myosin during intense muscle contractions
changes significantly its kinetic and regulatory properties
(in a substrate concentration-dependent manner (Hisatome
et al. 1998; Rundell et al. 1992). Moreover, the enzyme can
change its subunit composition, forming oligomers com-
posed of products encoded by different AMPD genes
(Fortuin et al. 1996; Mahnke-Zizelman et al. 1998). All
these regulatory mechanisms are noticeable for control of
the enzymatic activity during muscle contractions in vivo.
The activity of AMPD is generally associated with high
energy demand and sustained ATP turnover (Hancock et al.
2006).
Mammalian AMPD undergoes limited proteolysis
in vitro; the degradation is limited to the N-terminal
regions of the AMPD isozymes. Proteolysis of the N-ter-
minal fragments does not reduce significantly catalytic
activity of the enzyme (Mahnke-Zizelman and Sabina
2001). The use of new recombinant technologies allowed
to synthesize full-size AMPD proteins with intact N-ter-
minal fragments (Sabina et al. 1984).
Similar to the other two products of AMPD family
genes, also AMPD1 undergoes the process of limited
proteolysis. This is normally observed during purification
of the enzyme and its further storage. The molecular mass
of AMPD1 subunit isolated freshly from autopsied human
skeletal muscle (60–72 kDa) (Mahnke-Zizelman and
Sabina 2001; Stankiewicz 1981) differs markedly from that
predicted on the basis of cDNA sequencing (86–87 kDa)
(Sabina et al. 1984). This discrepancy is most probably a
result of proteolysis taking place during the process of
purification (Sabina et al. 1984). While the in vitro prote-
olysis of the enzyme is irreversible (Haas and Sabina
2003). It is possible that removal of fragment about 20 kDa
from control sample could be ablation of N-terminal
determining tissue specific properties of AMPD isoform,
which may be responsible for metabolism of muscle MG
patients in observed disease symptoms.
MG alters energetic metabolism of exercising skeletal
muscles. Compared to the controls, patients with moderate
to severe MG were characterized by significantly higher
end-exercise muscle Pi/ATP ratio and significantly lower
end-exercise muscle pH (Lindquist 2008; Ko et al. 2008).
While the muscular weakness is mainly a consequence of
impaired neuromuscular transmission, it also partially
results from reduced excitation–contraction coupling (Pa-
gala et al. 1990).
It is possible that more stable isoform AMPD1 in MG
muscles may be responsible for weakness and fatigability
of skeletal muscles. Further studies, because of small
sample size which limit the study, are necessary to explain
if the changes in myocyte metabolism, induced by
impaired neuromuscular signal transmission, may also
influence the physiological function of muscular AMPD
isozymes.
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